7,247 XNAS Volume
XNAS 17 Mar, 2025 12:58 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Oren Gilad | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 3.92 per share. | 23 Oct 2024 | 500 | 333,395 (1%) | 0% | 3.9 | 1,958 | Common Stock |
| Marc Duey | Director | Sale of securities on an exchange or to another person at price $ 4.58 per share. | 18 Oct 2024 | 6,462 | 233,651 (1%) | 0% | 4.6 | 29,583 | Common Stock |
| Marc Duey | Director | Purchase of securities on an exchange or from another person at price $ 4.39 per share. | 16 Oct 2024 | 30,000 | 240,113 (1%) | 0% | 4.4 | 131,700 | Common Stock |
| Oren Gilad | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 2.90 per share. | 15 Oct 2024 | 250 | 332,895 (1%) | 0% | 2.9 | 725 | Common Stock |
| Marc Duey | Director | Purchase of securities on an exchange or from another person at price $ 2.58 per share. | 14 Oct 2024 | 190 | 210,113 (1%) | 0% | 2.6 | 490 | Common Stock |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Purchase of securities on an exchange or from another person at price $ 2.46 per share. | 11 Oct 2024 | 50 | 19,368 (0%) | 0% | 2.5 | 123 | Common Stock |
| Bernd R. Seizinger | Director | Purchase of securities on an exchange or from another person at price $ 2.68 per share. | 11 Oct 2024 | 10,000 | 44,730 (0%) | 0% | 2.7 | 26,800 | Common Stock |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Purchase of securities on an exchange or from another person at price $ 2.61 per share. | 10 Oct 2024 | 450 | 19,318 (0%) | 0% | 2.6 | 1,175 | Common Stock |
| Oren Gilad | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 2.59 per share. | 10 Oct 2024 | 1,000 | 332,645 (1%) | 0% | 2.6 | 2,590 | Common Stock |
| Oren Gilad | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 2.54 per share. | 10 Oct 2024 | 150 | 331,645 (1%) | 0% | 2.5 | 381 | Common Stock |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,185 | 4,185 | - | - | Stock Options (Right to Buy) | |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 1,045 | 9,184 (0%) | 0% | 0 | Common Stock | |
| Bernd R. Seizinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,185 | 4,185 | - | - | Stock Options (Right to Buy) | |
| Bernd R. Seizinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 1,045 | 34,730 (0%) | 0% | 0 | Common Stock | |
| Richard Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,185 | 4,185 | - | - | Stock Options (Right to Buy) | |
| Richard Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 1,045 | 2,074 (0%) | 0% | 0 | Common Stock | |
| Michael Grissinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 1,045 | 1,844 (0%) | 0% | 0 | Common Stock | |
| Michael Grissinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,185 | 4,185 | - | - | Stock Options (Right to Buy) | |
| Rifat Pamukcu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,185 | 4,185 | - | - | Stock Options (Right to Buy) | |
| Rifat Pamukcu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 1,045 | 4,401 (0%) | 0% | 0 | Common Stock | |
| Marc Duey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 1,045 | 209,923 (1%) | 0% | 0 | Common Stock | |
| Marc Duey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,185 | 4,185 | - | - | Stock Options (Right to Buy) | |
| Nadeem Q. Mirza | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 6,730 | 6,730 (0%) | 0% | 0 | Common Stock | |
| Nadeem Q. Mirza | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 26,920 | 26,920 | - | - | Stock Options (Right to Purchase) | |
| Hamill P. John | SrVP/CFO/Prin Fin & Acct Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 3,365 | 18,868 (0%) | 0% | 0 | Common Stock | |
| Hamill P. John | SrVP/CFO/Prin Fin & Acct Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 13,460 | 13,460 | - | - | Stock Options (Right to Buy) | |
| Oren Gilad | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 6,725 | 331,495 (1%) | 0% | 0 | Common Stock | |
| Gilad Oren | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 26,900 | 26,900 | - | - | Stock Options (Right to Buy) | |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Purchase of securities on an exchange or from another person at price $ 7.29 per share. | 13 Mar 2024 | 1,010 | 15,503 (0%) | 0% | 7.3 | 7,363 | Common Stock |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 505 | 505 | - | - | Tranche B Warrant | |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 505 | 505 | - | - | Tranche A Warrant | |
| John B. Henneman | Director | Purchase of securities on an exchange or from another person at price $ 7.29 per share. | 13 Mar 2024 | 6,860 | 8,139 (0%) | 0% | 7.3 | 50,009 | Common Stock |
| John B. Henneman | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 3,430 | 3,430 | - | - | Tranche A Warrant | |
| John B. Henneman | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 3,430 | 3,430 | - | - | Tranche B Warrant | |
| Bernd R. Seizinger | Director | Purchase of securities on an exchange or from another person at price $ 7.29 per share. | 13 Mar 2024 | 6,860 | 33,685 (0%) | 0% | 7.3 | 50,009 | Common Stock |
| Bernd R. Seizinger | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 3,430 | 3,430 | - | - | Tranche B Warrant | |
| Bernd R. Seizinger | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 3,430 | 3,430 | - | - | Tranche A Warrant | |
| Oren Gilad | Director, President, CEO | Purchase of securities on an exchange or from another person at price $ 7.29 per share. | 13 Mar 2024 | 2,000 | 324,770 (1%) | 0% | 7.3 | 14,580 | Common Stock |
| Oren Gilad | Director, President, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 1,000 | 1,000 | - | - | Tranche A Warrant | |
| Oren Gilad | Director, President, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 1,000 | 1,000 | - | - | Tranche B Warrant | |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 2,000 | 2,000 | - | - | Stock Options (Right to Buy) | |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 500 | 1,279 (0%) | 0% | 0 | Common Stock | |
| Bernd R. Seizinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 2,000 | 2,000 | - | - | Stock Options (Right to Buy) | |
| Bernd R. Seizinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 500 | 26,825 (0%) | 0% | 0 | Common Stock | |
| Jean-Pierre Bizzari | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 12,500 | 12,500 | - | - | Stock Options (Right to Buy) | |
| Richard Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 500 | 1,029 (0%) | 0% | 0 | Common Stock | |
| Richard Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 2,000 | 2,000 | - | - | Stock Options (Right to Buy) | |
| Michael Grissinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 2,000 | 2,000 | - | - | Stock Options (Right to Buy) | |
| Michael Grissinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 500 | 799 (0%) | 0% | 0 | Common Stock | |
| Marc Duey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 500 | 208,878 (0%) | 0% | 0 | Common Stock | |
| Marc Duey | Director | 23 Aug 2023 | 4,009,690 | 4,167,589 (19%) | 19% | 0 | Common Stock | ||
| Marc Duey | Director | 23 Aug 2023 | 11,610 | 602 (0%) | 0% | 0 | Common Stock | ||
| Marc Duey | Director | 23 Aug 2023 | 400,969 | 0 | - | - | Series A Non-Voting Convertible Preferred Stock | ||
| Marc Duey | Director | 23 Aug 2023 | 1,161 | 0 | - | - | Series A Non-Voting Convertible Preferred Stock | ||
| Marc Duey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 2,000 | 2,000 | - | - | Stock Options (Right to Buy) | |
| Bernd R. Seizinger | Director | Purchase of securities on an exchange or from another person at price $ 3.68 per share. | 06 Jun 2023 | 6,029 | 26,325 (0%) | 0% | 3.7 | 22,192 | Common Stock |
| Bernd R. Seizinger | Director | Purchase of securities on an exchange or from another person at price $ 3.63 per share. | 06 Jun 2023 | 4,068 | 20,296 (0%) | 0% | 3.6 | 14,764 | Common Stock |
| Gabriela Gruia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 12,500 | 12,500 | - | - | Stock Options (Right to Buy) | |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Grant, award, or other acquisition of securities at price $ 5.25 per share. | 27 Feb 2023 | 1,000 | 14,493 (0%) | 0% | 5.3 | 5,250 | Common Stock |
| John P. Hamill | SrVP/CFO/Prin. Fin&Acctg. Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 269,879 | 269,879 (1%) | 1% | 0 | Common Stock | |
| John P. Hamill | SrVP/CFO/Prin. Fin&Acctg. Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 539,758 | 539,758 | - | - | Employee Stock Option (Right to Buy) | |
| Oren Gilad | Director, President, CEO | 23 Aug 2022 | 6,045,100 | 6,375,414 (30%) | 28% | 0 | Common Stock | ||
| Oren Gilad | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2022 | 16,000 | 16,000 | - | - | Stock Options (Right to Buy) | |
| Oren Gilad | Director, President, CEO | 23 Aug 2022 | 604,510 | 0 | - | - | Series A Non-Voting Convertible Preferred Stock | ||
| Oren Gilad | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2022 | 4,000 | 322,770 (1%) | 0% | 0 | Common Stock | |
| Rif Pamukcu | Director | 23 Aug 2022 | 271,870 | 14,108 (0%) | 1% | 0 | Common Stock | ||
| Rif Pamukcu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2022 | 500 | 3,356 (0%) | 0% | 0 | Common Stock | |
| Rif Pamukcu | Director | 23 Aug 2022 | 49,280 | 57,142 (0%) | 0% | 0 | Common Stock | ||
| Rif Pamukcu | Director | 23 Aug 2022 | 27,187 | 0 | - | - | Series A Non-Voting Convertible Preferred Stock | ||
| Rif Pamukcu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2022 | 2,000 | 2,000 | - | - | Stock Options (Right to Buy) | |
| Rif Pamukcu | Director | 23 Aug 2022 | 4,928 | 0 | - | - | Series A Non-Voting Convertible Preferred Stock | ||
| Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 32,400 | 259,246 (1%) | 0% | 0 | Common Stock | |
| Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 47,600 | 47,600 | - | - | Stock Option (right to Buy) | |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 5,995 | 15,605 (0%) | 0% | 0 | Common Stock | |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 29,575 | 29,575 | - | - | Stock Option (right to Buy) | |
| Bernd R. Seizinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 29,575 | 29,575 | - | - | Stock Option (right to Buy) | |
| Bernd R. Seizinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 5,995 | 324,575 (1%) | 0% | 0 | Common Stock | |
| Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 89,200 | 89,200 | - | - | Stock Option (right to Buy) | |
| Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 60,800 | 145,065 (0%) | 0% | 0 | Common Stock | |
| Richard Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 29,575 | 29,575 | - | - | Stock Option (right to Buy) | |
| Richard Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 5,995 | 10,605 (0%) | 0% | 0 | Common Stock | |
| Michael Grissinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 5,995 | 5,995 (0%) | 0% | 0 | Common Stock | |
| Michael Grissinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 29,575 | 29,575 | - | - | Stock Option (right to Buy) | |
| Gregory A. Korbel | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 24,300 | 45,762 (0%) | 0% | 0 | Common Stock | |
| Gregory A. Korbel | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 35,700 | 35,700 | - | - | Stock Option (right to Buy) | |
| Oren Gilad | President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 148,700 | 148,700 | - | - | Stock Option (right to Buy) | |
| Oren Gilad | President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 101,300 | 330,314 (1%) | 0% | 0 | Common Stock | |
| Rif Pamukcu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 29,575 | 29,575 | - | - | Stock Option (right to Buy) | |
| Rif Pamukcu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 5,995 | 7,862 (0%) | 0% | 0 | Common Stock | |
| Marc Duey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 29,575 | 29,575 | - | - | Stock Option (right to Buy) | |
| Marc Duey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 5,995 | 157,899 (0%) | 0% | 0 | Common Stock | |
| Christian Stanton Schade | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.81 per share. | 03 Jun 2022 | 65,770 | 226,846 (1%) | 0% | 0.8 | 52,945 | Common Stock |
| Scott M. Coiante | Director, SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.81 per share. | 03 Jun 2022 | 35,284 | 84,265 (0%) | 0% | 0.8 | 28,404 | Common Stock |
| Eyal C. Attar | Director, SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.81 per share. | 03 Jun 2022 | 32,667 | 57,233 (0%) | 0% | 0.8 | 26,297 | Common Stock |
| Gregory A. Korbel | Director, SVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.81 per share. | 03 Jun 2022 | 8,390 | 21,462 (0%) | 0% | 0.8 | 6,754 | Common Stock |
| Christian Stanton Schade | Director, Chairman & CEO | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 18 May 2022 | 37,500 | 292,616 (1%) | 0% | 0.6 | 24,124 | Common Stock |
| Bernd R. Seizinger | Director | Purchase of securities on an exchange or from another person at price $ 0.71 per share. | 18 May 2022 | 50,000 | 318,580 (1%) | 0% | 0.7 | 35,500 | Common Stock |
| Christian Stanton Schade | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 427,700 | 427,700 | - | - | Stock Option (right to Buy) | |
| Christian Stanton Schade | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 100,100 | 255,116 (1%) | 0% | 0 | Common Stock | |
| Scott M. Coiante | Director, SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 42,900 | 119,549 (0%) | 0% | 0 | Common Stock | |
| Scott M. Coiante | Director, SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 185,900 | 185,900 | - | - | Stock Option (right to Buy) | |
| Eyal C. Attar | Director, SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 185,900 | 185,900 | - | - | Stock Option (right to Buy) | |
| Eyal C. Attar | Director, SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 42,900 | 89,900 (0%) | 0% | 0 | Common Stock | |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 24,700 | 43,700 (0%) | 0% | 0 | Common Stock | |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 100,000 | 100,000 | - | - | Stock Option (right to Buy) | |
| Gregory A. Korbel | Director, SVP, Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.82 per share. | 10 Mar 2022 | 1,989 | 29,852 (0%) | 0% | 1.8 | 3,620 | Common Stock |
| Gregory A. Korbel | Director, SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 72,600 | 72,600 | - | - | Stock Option (right to Buy) | |
| Gregory A. Korbel | Director, SVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 16,000 | 31,841 (0%) | 0% | 0 | Common Stock | |
| Eyal C. Attar | SVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.73 per share. | 28 Feb 2022 | 36,000 | 47,000 (0%) | 0% | 1.7 | 62,280 | Common Stock |
| Christian Stanton Schade | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.74 per share. | 25 Feb 2022 | 21,644 | 155,016 (0%) | 0% | 1.7 | 37,661 | Common Stock |
| Scott M. Coiante | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.74 per share. | 25 Feb 2022 | 14,817 | 76,649 (0%) | 0% | 1.7 | 25,782 | Common Stock |
| Gregory A. Korbel | SVP, Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.74 per share. | 25 Feb 2022 | 1,326 | 15,841 (0%) | 0% | 1.7 | 2,307 | Common Stock |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.92 per share. | 01 Oct 2021 | 50,000 | 69,000 (0%) | 0% | 0.9 | 46,000 | Common Stock |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 50,000 | 30,587 | - | - | Stock Option (right to Buy) | |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 4.89 per share. | 01 Oct 2021 | 50,000 | 19,000 (0%) | 0% | 4.9 | 244,500 | Common Stock |
| Gregory A. Korbel | SVP, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 27,500 | 25,245 | - | - | Stock Option (right to Buy) | |
| Gregory A. Korbel | SVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 4.89 per share. | 01 Oct 2021 | 27,500 | 17,167 (0%) | 0% | 4.9 | 134,475 | Common Stock |
| Gregory A. Korbel | SVP, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.92 per share. | 01 Oct 2021 | 27,500 | 44,667 (0%) | 0% | 0.9 | 25,300 | Common Stock |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 4.97 per share. | 20 Sep 2021 | 25,000 | 19,000 (0%) | 0% | 5.0 | 124,250 | Common Stock |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 25,000 | 80,587 | - | - | Stock Option (right to Buy) | |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.92 per share. | 20 Sep 2021 | 25,000 | 44,000 (0%) | 0% | 0.9 | 23,000 | Common Stock |
| Gregory A. Korbel | SVP, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.92 per share. | 20 Sep 2021 | 27,500 | 44,667 (0%) | 0% | 0.9 | 25,300 | Common Stock |
| Gregory A. Korbel | SVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 4.98 per share. | 20 Sep 2021 | 5,460 | 17,167 (0%) | 0% | 5.0 | 27,191 | Common Stock |
| Gregory A. Korbel | SVP, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 27,500 | 52,745 | - | - | Stock Option (right to Buy) | |
| Gregory A. Korbel | SVP, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 4.97 per share. | 20 Sep 2021 | 27,500 | 17,167 (0%) | 0% | 5.0 | 136,675 | Common Stock |
| Eyal C. , Attar | SVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.68 per share. | 16 Sep 2021 | 15,968 | 83,000 (0%) | 0% | 4.7 | 74,730 | Common Stock |
| Gregory A. Korbel | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.59 per share. | 10 Sep 2021 | 1,724 | 22,627 (0%) | 0% | 4.6 | 7,913 | Common Stock |
| Scott M. Coiante | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.98 per share. | 25 Aug 2021 | 7,534 | 91,466 (0%) | 0% | 4.0 | 29,985 | Common Stock |
| Eyal C. , Attar | SVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.98 per share. | 25 Aug 2021 | 9,032 | 98,968 (0%) | 0% | 4.0 | 35,947 | Common Stock |
| Gregory A. Korbel | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.98 per share. | 25 Aug 2021 | 1,149 | 24,351 (0%) | 0% | 4.0 | 4,573 | Common Stock |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 22,750 | 22,750 | - | - | Stock Option (Right to Buy) | |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 4,610 | 9,610 (0%) | 0% | 0 | Common Stock | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 4,610 | 4,610 (0%) | 0% | 0 | Common Stock | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 22,750 | 22,750 | - | - | Stock Option (Right to Buy) | |
| Bernd R. Seizinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 22,750 | 22,750 | - | - | Stock Option (Right to Buy) | |
| Bernd R. Seizinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 4,610 | 268,580 (1%) | 0% | 0 | Common Stock | |
| Richard Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 4,610 | 4,610 (0%) | 0% | 0 | Common Stock | |
| Richard Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 22,750 | 22,750 | - | - | Stock Option (Right to Buy) | |
| Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 4,610 | 4,610 (0%) | 0% | 0 | Common Stock | |
| Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 22,750 | 22,750 | - | - | Stock Option (Right to Buy) | |
| Gregory A. Korbel | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 15,000 | 25,500 (0%) | 0% | 0 | Common Stock | |
| Christian Stanton Schade | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 329,000 | 329,000 | - | - | Stock Option (right to Buy) | |
| Christian Stanton Schade | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 77,000 | 77,160 (0%) | 0% | 0 | Common Stock | |
| Christian Stanton Schade | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 88,500 | 176,660 (0%) | 0% | 0 | Common Stock | |
| Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 63,500 | 99,000 (0%) | 0% | 0 | Common Stock | |
| Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 33,000 | 35,500 (0%) | 0% | 0 | Common Stock | |
| Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 143,000 | 143,000 | - | - | Stock Option (right to Buy) | |
| Eyal C. , Attar | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 75,000 | 108,000 (0%) | 0% | 0 | Common Stock | |
| Eyal C. , Attar | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 143,000 | 143,000 | - | - | Stock Option (right to Buy) | |
| Eyal C. , Attar | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 33,000 | 33,000 (0%) | 0% | 0 | Common Stock | |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 82,000 | 82,000 | - | - | Stock Option (right to Buy) | |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 19,000 | 19,000 (0%) | 0% | 0 | Common Stock | |
| Gregory A. Korbel | VP of Business Devt | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 41,100 | 41,100 | - | - | Stock Option (right to Buy) | |
| Gregory A. Korbel | VP of Business Devt | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 10,000 | 10,500 (0%) | 0% | 0 | Common Stock | |
| Gregory S. Wessels | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 66,000 | 66,000 | - | - | Stock Option (right to Buy) | |
| Gregory S. Wessels | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 16,000 | 16,000 (0%) | 0% | 0 | Common Stock | |
| Michael A. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2020 | 12,000 | 12,000 | - | - | Stock Option (right to Buy) | |
| Gregory S. Wessels | SVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2020 | 14,700 | 14,700 | - | - | Stock Option (right to Buy) | |
| Scott M. Rocklage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 5,600 | 5,600 | - | - | Stock Option (right to Buy) | |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 5,600 | 5,600 | - | - | Stock Option (right to Buy) | |
| Bernd R. Seizinger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 5,600 | 5,600 | - | - | Stock Option (right to Buy) | |
| Johan Christenson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 5,600 | 5,600 | - | - | Stock Option (right to Buy) | |
| Jonathan Hepple | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 5,600 | 5,600 | - | - | Stock Option (right to Buy) | |
| Richard Peters | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2020 | 7,000 | 7,000 | - | - | Stock Option (right to Buy) | |
| Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2020 | 7,000 | 7,000 | - | - | Stock Option (right to Buy) | |
| Scott M. Rocklage | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 33.30 per share. | 16 Jun 2020 | 4,807 | 75,965 (0%) | 0% | 33.3 | 160,073 | Common Stock |
| Scott M. Rocklage | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 33.30 per share. | 16 Jun 2020 | 115,357 | 1,823,192 (8%) | 0% | 33.3 | 3,841,388 | Common Stock |
| Scott M. Rocklage | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 28.75 per share. | 11 Jun 2020 | 9,800 | 80,772 (0%) | 0% | 28.8 | 281,776 | Common Stock |
| Scott M. Rocklage | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 28.75 per share. | 11 Jun 2020 | 235,200 | 1,938,549 (9%) | 1% | 28.8 | 6,762,635 | Common Stock |
| Scott M. Rocklage | Director | Sale of securities on an exchange or to another person at price $ 35.15 per share. | 19 May 2020 | 244,800 | 2,173,748 (10%) | 1% | 35.2 | 8,604,720 | Common Stock |
| Scott M. Rocklage | Director | Sale of securities on an exchange or to another person at price $ 35.15 per share. | 19 May 2020 | 10,200 | 90,572 (0%) | 0% | 35.2 | 358,530 | Common Stock |
| Christian S. Schade | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2020 | 127,000 | 127,000 | - | - | Stock Option (right to Buy) | |
| Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2020 | 55,000 | 55,000 | - | - | Stock Option (right to Buy) | |
| Eyal C. , Attar | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2020 | 55,000 | 55,000 | - | - | Stock Option (right to Buy) | |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2020 | 31,600 | 31,600 | - | - | Stock Option (right to Buy) | |
| Gregory A. Korbel | VP of Business Devt | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2020 | 12,800 | 12,800 | - | - | Stock Option (right to Buy) | |
| Christian S. Schade | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 1,000 | 1,000 (0%) | 0% | 15 | 15,000 | Common Stock |
| Christian S. Schade | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2019 | 306,085 | 306,085 | - | - | Stock Option (right to Buy) | |
| Christian S. Schade | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 5,000 | 5,000 (0%) | 0% | 15 | 75,000 | Common Stock |
| Christian S. Schade | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 1,000 | 1,000 (0%) | 0% | 15 | 15,000 | Common Stock |
| Christian S. Schade | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 1,000 | 1,000 (0%) | 0% | 15 | 15,000 | Common Stock |
| Christian S. Schade | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 1,000 | 1,000 (0%) | 0% | 15 | 15,000 | Common Stock |
| Christian S. Schade | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 1,000 | 1,000 (0%) | 0% | 15 | 15,000 | Common Stock |
| Christian S. Schade | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 1,000 | 1,000 (0%) | 0% | 15 | 15,000 | Common Stock |
| Scott M. Rocklage | None | 07 Oct 2019 | 79,746 | 80,253 (0%) | 0% | 0 | Common Stock | ||
| Scott M. Rocklage | None | 07 Oct 2019 | 1,913,910 | 1,926,073 (9%) | 9% | 0 | Common Stock | ||
| Scott M. Rocklage | None | 07 Oct 2019 | 20,519 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Scott M. Rocklage | None | 07 Oct 2019 | 492,475 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Scott M. Rocklage | None | 07 Oct 2019 | 79,746 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Scott M. Rocklage | None | 07 Oct 2019 | 1,913,910 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Scott M. Rocklage | None | 07 Oct 2019 | 20,519 | 100,772 (0%) | 0% | 0 | Common Stock | ||
| Scott M. Rocklage | None | 07 Oct 2019 | 492,475 | 2,418,548 (12%) | 2% | 0 | Common Stock | ||
| John B. Henneman | None | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 5,000 | 5,000 (0%) | 0% | 15 | 75,000 | Common Stock |
| John B. Henneman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2019 | 18,407 | 18,407 | - | - | Stock Option (right to Buy) | |
| Guido Magni | None | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 6,500 | 6,500 (0%) | 0% | 15 | 97,500 | Common Stock |
| Bernd R. Seizinger | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2019 | 263,970 | 0 | - | - | Stock Option (right to buy) | |
| Bernd R. Seizinger | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.07 per share. | 07 Oct 2019 | 263,970 | 263,970 (1%) | 1% | 0.1 | 18,478 | Common Stock |
| Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2019 | 150,824 | 150,824 | - | - | Stock Option (right to Buy) | |
| Scott M. Coiante | SVP, Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 2,500 | 2,500 (0%) | 0% | 15 | 37,500 | Common Stock |
| Eyal C. , Attar | SVP, Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 200 | 200 (0%) | 0% | 15 | 3,000 | Common Stock |
| Eyal C. , Attar | SVP, Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 200 | 200 (0%) | 0% | 15 | 3,000 | Common Stock |
| Eyal C. , Attar | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2019 | 77,630 | 77,630 | - | - | Stock Option (right to Buy) | |
| Lars Abrahmsen | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2019 | 77,630 | 77,630 | - | - | Stock Option (right to Buy) | |
| Gregory A. Korbel | VP of Business Devt | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2019 | 64,322 | 64,322 | - | - | Stock Option (right to Buy) | |
| Gregory A. Korbel | VP of Business Devt | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 500 | 500 (0%) | 0% | 15 | 7,500 | Common Stock |
| Johan Christenson | None | 07 Oct 2019 | 427,496 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Johan Christenson | None | 07 Oct 2019 | 1,661,382 | 1,671,941 (8%) | 8% | 0 | Common Stock | ||
| Johan Christenson | None | 07 Oct 2019 | 427,496 | 2,099,437 (10%) | 2% | 0 | Common Stock | ||
| Johan Christenson | None | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 07 Oct 2019 | 266,667 | 2,366,104 (11%) | 1% | 15 | 4,000,005 | Common Stock |
| Johan Christenson | None | 07 Oct 2019 | 1,661,382 | 0 | - | - | Series B Convertible Preferred Stock |